证券代码：300452 证券简称：山河药辅 公告编号：2025-052 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于 2025 年第三季度可转债转股情况的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、"山河转债"（债券代码：123199）的转股期限为 2023 年 12 月 18 日起至 2029 年 6 月 11 日；最新的转股价格为人民币 13.30 元/股； 2、2025 年第三季度，共有 50 张"山河转债"（票面金额共计 5,000 元人民币）完成转股，合计转成 375 股"山河药辅"股票； 3、截至 2025 年第三季度末，共有 1,787 张"山河转债"（票面 金额共计 178,700 元人民币）完成转股，合计转成 12,191 股"山河 药辅"股票；公司剩余可转债数量为 3,198,213 张，剩余票面总金 额为 319,821,300 元人民币。 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市 公司自律监管指引第 15 号——可转换公司债券》的有关规定，安徽 山河药用辅料股份有限公司（以下 ...

北京市东城区朝阳门内大街南竹杆胡同 2 号银河 SOHO5 号楼 邮编：100010 电话：（8610）6642 8877 传真：（8610）6642 6100 Building 5, Galaxy SOHO, No.2 Nanzhuganhutong,ChaoyangmenneiAvenue, Dongcheng District,Beijing, 100010 中诚信国际认为，本次公司控股股东、实际控制人变更事项系夫妻共同财产 分割及遗产继承事项产生，目前公司经营及治理结构保持稳定，上述事项暂未对 公司整体信用水平产生重大不利影响，中诚信国际将持续关注上述股权变更事 项对公司未来经营管理和发展战略的影响。 特此公告 中诚信国际信用评级有限责任公司 中诚信国际关于关注安徽山河药用辅料股份有限公司 控股股东、实际控制人发生变更的公告 安徽山河药用辅料股份有限公司（以下简称"山河药辅"或"公司"）发行 的"山河转债"由中诚信国际信用评级有限责任公司（以下简称"中诚信国际"） 进行相关评级工作。 近日，公司发布《安徽山河药用辅料股份有限公司关于控股股东、实际控制 人发生变更暨股东权益变动的提示性公告》和《安徽山河 ...

Group 1 - Pingzhi Information has been selected as the eighth candidate for the "2025 China Unicom General Server Centralized Procurement Project" with a bid amount of approximately 451 million yuan [1] - The project involves the procurement of general servers primarily for cloud computing infrastructure [1] - Pingzhi Information was established in November 2002 and focuses on communication equipment, computing power, and operator equity products [1] Group 2 - Betta Pharmaceuticals has submitted an application for the issuance of H shares and listing on the Hong Kong Stock Exchange [2] - Betta Pharmaceuticals was founded in January 2003 and specializes in the production and sales of innovative drugs [2] Group 3 - Guangli Micro plans to sign an agreement with Zhejiang University to establish a joint research center for silicon photonics technology and measurement equipment [3] - The company will invest no less than 15 million yuan over three years for the center's development [3] - Guangli Micro was founded in August 2003 and provides a range of services including integrated circuit manufacturing and design [3] Group 4 - Shanhe Pharmaceutical's controlling shareholder and actual controller has changed due to the passing of Yin Zhenglong, with his wife and daughter inheriting shares [4] - After the change, Wu Changhong holds 20.172% of the total shares, while Yin Zhiya holds 6.724% [4] - Shanhe Pharmaceutical was established in April 2001 and focuses on the research, production, and sales of pharmaceutical excipients [5] Group 5 - Hengwei Technology plans to acquire 75% of Shanghai Shuhang Information Technology Co., Ltd. through a combination of share issuance and cash payment [6] - The acquisition will make Shuhang Technology a subsidiary of Hengwei Technology [6] - Hengwei Technology was founded in March 2003 and specializes in intelligent system solutions [7] Group 6 - Shougang Co. intends to repurchase its A-shares for an amount between 260 million yuan and 520 million yuan [8] - The repurchase will be used for implementing an equity incentive plan [8] - Shougang Co. was established in October 1999 and focuses on the production and sales of steel products [9] Group 7 - Pulit plans to build a 6GWh sodium-ion battery production base in Sichuan with a total investment of approximately 800 million yuan [10] - The project will be constructed in two phases, with the first phase having a capacity of 2GWh [10] - Pulit was founded in October 1999 and specializes in high polymer new materials and battery production [10] Group 8 - Saisir has proposed a cash dividend of 3.1 yuan per 10 shares for its A-share shareholders [10] - Saisir was established in May 2007 and focuses on the research, manufacturing, and sales of new energy vehicles [10] Group 9 - Guangyang Co. plans to establish a wholly-owned subsidiary for the development of precision components for robots [11] - The investment is part of a project to produce high-end components for new energy vehicles and robots [11] - Guangyang Co. was founded in April 1995 and specializes in precision components for various vehicles and equipment [11] Group 10 - Conch New Materials intends to acquire a 51% stake in North China Industrial Plastics Co., Ltd. for approximately 95.27 million yuan [12] - The acquisition will make North China Plastics a subsidiary of Conch New Materials [12] - Conch New Materials was established in October 1996 and focuses on the production and sales of plastic profiles and aluminum profiles [12] Group 11 - Daikin Heavy Industries has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [13] - The company specializes in the production and sales of offshore wind power equipment [13] - Daikin Heavy Industries was founded in September 2003 [13] Group 12 - Tengya Precision plans to invest up to 8 million USD to establish a subsidiary in Vietnam for the production of garden robots and electric tools [14] - The project will involve leasing a factory in Dong Nai Province [14] - Tengya Precision was established in August 2000 and focuses on power tools and building hardware [15] Group 13 - Luoxin Pharmaceutical plans to raise up to 207 million yuan through a private placement for innovative drug research and development [16] - The funds will primarily support clinical research for specific innovative drugs [16] - Luoxin Pharmaceutical was founded in May 1998 and specializes in pharmaceutical product development [17] Group 14 - *ST Guohua's subsidiary has become the first candidate for a project with a bid of 236 million yuan [18] - The project involves a 90-day construction period [18] - *ST Guohua was established in May 1986 and focuses on mobile network security [19] Group 15 - Su Chen Technology plans to acquire 60% of Likong Technology for a total price of 192 million yuan [20] - The acquisition will make Likong Technology a secondary subsidiary of Su Chen Technology [20] - Su Chen Technology was founded in February 2006 and specializes in CAE software development [21] Group 16 - Qingmu Technology's major shareholder plans to reduce their stake by up to 276,000 shares [22] - The reduction is due to the shareholder's financial needs [22] - Qingmu Technology was established in August 2009 and provides comprehensive e-commerce operation services [23] Group 17 - Tongda Sea plans to acquire 40% of Jiangsu Sufuda Data Technology Co., Ltd. for 25.64 million yuan [24] - The acquisition will result in Tongda Sea holding 100% of Sufuda [24] - Tongda Sea was founded in March 1995 and provides information technology services for electronic government affairs [24] Group 18 - Rongsheng Development has signed a memorandum of cooperation to promote the development of the seaplane industry [25] - The cooperation will focus on infrastructure construction and talent training [25] - Rongsheng Development was established in December 1996 and specializes in real estate development [26] Group 19 - Jinma Amusement plans to repurchase 16.52% of its subsidiary for 60 million yuan [28] - The repurchase will convert the subsidiary into a wholly-owned entity [28] - Jinma Amusement was founded in November 2007 and focuses on amusement facilities and projects [28] Group 20 - Huilv Ecology plans to acquire 49% of Junheng Technology for 1.127 billion yuan [29] - The acquisition will make Junheng Technology a wholly-owned subsidiary [29] - Huilv Ecology was established in January 1990 and specializes in optical communication products and landscape engineering [30]

Group 1: Major Asset Restructuring - Guolin Technology is planning a significant asset restructuring by acquiring 91.07% of Xinjiang Kailianjie Petrochemical Co., Ltd. for cash, which will give the company control over Kailianjie, making it a subsidiary [1][2] Group 2: Equity Purchases and Stock Suspension - Diaowei is planning to purchase equity in Rongpai Semiconductor through a combination of issuing shares and cash payments, leading to a stock suspension from September 29, 2025, for up to 10 trading days [3] - Bicheng Co. is also planning to acquire 55% of Shanghai Canxi Engineering Equipment Co., Ltd. through issuing shares and cash, with a stock suspension starting September 30, 2025, for up to 5 trading days [7] Group 3: Changes in Control - Shanhe Pharmaceutical Auxiliary announced a change in its controlling shareholder and actual controller to Wu Changhong due to the inheritance following the death of the previous controller, Yin Zhenglong [4] Group 4: Earnings Forecasts - Yinglian Co. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531.13% to 1672.97%, driven by the fast-moving consumer goods metal packaging sector [5] - Dalian Heavy Industry anticipates a net profit of 474 million to 508 million yuan for the same period, reflecting a growth of 19.91% to 28.52% year-on-year, attributed to steady revenue growth [5] Group 5: Fundraising and Projects - Zhongcai Technology plans to raise up to 4.481 billion yuan through a private placement to fund projects related to low dielectric fiber cloth production and to repay government funds [8] - Luoxin Pharmaceutical is also looking to raise up to 842.4 million yuan for innovative drug research and development and facility upgrades [8] Group 6: Regulatory Actions - *ST Xingnong has been investigated by the China Securities Regulatory Commission for suspected information disclosure violations [9] - Other companies, including Youkeshi and Woton Technology, are also involved in various regulatory and investment activities, including share buybacks and strategic partnerships [10][14]

格隆汇9月29日丨山河药辅(300452.SZ)公布，在本次权益变动前，吴长虹女士、尹稚雅女士未直接或间 接持有公司股份。2025年8月26日，公司原控股股东、实际控制人尹正龙先生逝世。尹正龙先生直接持 有公司63,057,454股股份，占公司总股本的26.896%，为公司原控股股东、实际控制人。 根据淮南市正诚公证处出具的《公证书》（2025）皖淮正公证字第7078号），尹正龙先生生前无遗嘱， 亦未与他人签订遗赠扶养协议。根据《民法典》相关规定，被继承人尹正龙先生遗产应由其妻子吴长 虹、女儿尹稚雅两人共同继承。本次权益变动后吴长虹女士将直接持有山河药辅47,293,091股股票，占 山河药辅总股本的20.172%，尹稚雅女士将直接持有山河药辅15,764,363股股票，占山河药辅总股本的 6.724%。同时，吴长虹女士与尹稚雅女士签署了《表决权委托协议》，尹稚雅女士将其所持有山河药 辅全部股份的身份性权利，包括（但不限于）参会权、提名权、提案权、表决权等身份性权利全部委托 吴长虹女士行使。至此，吴长虹女士持有63,057,454股山河药辅表决权，占公司有表决权股份总数的比 例为26.896%。山河药辅控股股 ...

根据淮南市正诚公证处出具的《公证书》（2025）皖淮正公证字第7078号），尹正龙先生生前无遗嘱， 亦未与他人签订遗赠扶养协议。根据《民法典》相关规定，被继承人尹正龙先生遗产应由其妻子吴长 虹、女儿尹稚雅两人共同继承。本次权益变动后吴长虹女士将直接持有山河药辅47,293,091股股票，占 山河药辅总股本的20.172%，尹稚雅女士将直接持有山河药辅15,764,363股股票，占山河药辅总股本的 6.724%。同时，吴长虹女士与尹稚雅女士签署了《表决权委托协议》，尹稚雅女士将其所持有山河药 辅全部股份的身份性权利，包括（但不限于）参会权、提名权、提案权、表决权等身份性权利全部委托 吴长虹女士行使。至此，吴长虹女士持有63,057,454股山河药辅表决权，占公司有表决权股份总数的比 例为26.896%。山河药辅控股股东、实际控制人由尹正龙先生变更为吴长虹女士。 本次权益变动完成后，公司控股股东、实际控制人由尹正龙先生变更为吴长虹女士，尹稚雅女士为其一 致行动人。公司本次控股股东、实际控制人变更系因夫妻共同财产分割及遗产继承事项发生变动，不会 影响公司经营的稳定性，不会引起公司管理层变动，亦不会影响公司的独立性和 ...

山河药辅(300452.SZ)公告称，公司原控股股东、实际控制人尹正龙逝世后，其妻吴长虹和女儿尹稚雅 通过继承获得公司股份。本次权益变动后，吴长虹将直接持有山河药辅20.172%股份，尹稚雅直接持有 6.724%股份。同时，吴长虹与尹稚雅签署了《表决权委托协议》，尹稚雅将其所持有山河药辅全部股 份的身份性权利，包括参会权、提名权、提案权、表决权等身份性权利全部委托吴长虹行使。山河药辅 控股股东、实际控制人由尹正龙变更为吴长虹。 ...

证券代码:300452 证券简称:山河药辅 公告编号：2025-051 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于大股东签署《表决权委托协议》的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 一、本次表决权委托概述 原实际控制人、控股股东尹正龙先生遗产由其妻子吴长虹、女儿 尹稚雅 两人共同继承，继承后吴长虹女士将直接持有安徽山河药用 辅料股份有限公司（以下简称"公司"） 47,293,091 股股票，占公 司总股本的 20.172%，尹稚雅女士将直接持有公司 15,764,363 股股 票，占公司总股本的 6.724%。为促进公司长期稳定发展，近日，公 司收到尹稚雅女士和吴长虹女士签署的《表决权委托协议》，尹稚雅 女士将其所直接持有的公司股份共计 15,764,363 股表决权委托给 吴长虹女士。协议生效后，吴长虹女士持有的有表决权的股份合计 6 3,057,454 股表决权，约占公司有表决权股份总数的比例为 26.896%。 二、本次签署的《表决权委托协议》的主要内容 （一）甲方自愿将所持全部山河药辅股份的提案权、提名权及投 票权 ...

证券代码:300452 证券简称:山河药辅 公告编号：2025-050 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于控股股东、实际控制人发生变更暨股东权益变动的提示 性公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次权益变动系因公司原控股股东、实际控制人尹正龙先生 逝世后的遗产继承所致，尹正龙先生的配偶吴长虹女士及女儿尹稚雅 女士通过继承的方式获得上市公司股份，不会对公司产生重大不利影 响。 2、本次权益变动后，公司的控股股东、实际控制人由尹正龙先 生变更为吴长虹女士，尹稚雅女士为其一致行动人； 3、本次权益变动不触及要约收购。 安徽山河药用辅料股份有限公司（以下简称"公司"）于近日收 到吴长虹女士、尹稚雅女士出具的《安徽山河药用辅料股份有限公司 详式权益变动报告书》（以下简称"《详式权益变动报告书》"）， 现将相关情况公告如下： 一、本次权益变动基本情况 （一）本次权益变动情况 在本次权益变动前，吴长虹女士、尹稚雅女士未直接或间接持有 公司股份。 2025 年 8 月 26 日，公司原控股股东、实际控制人尹正龙先 ...

住所及通信地址：安徽省淮南市田家庵区XX号 安徽山河药用辅料股份有限公司 详式权益变动报告书 上市公司名称：安徽山河药用辅料股份有限公司 股票上市地点：深圳证券交易所 股票简称：山河药辅 股票代码：300452 信息披露义务人一：吴长虹 信息披露义务人二：尹稚雅 住所及通信地址：安徽省淮南市田家庵区XX号 股份变动性质：继承 签署日期：2025 年 9 月29日 安徽山河药用辅料股份有限公司 详式权益变动报告书 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号— —权益变动报告书》等法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书无需获得必要的授权和批准；其履行亦不 违反安徽山河药用辅料股份有限公司章程或内部规则中的任何条款，或与之相冲 突。 三、本报告书已全面披露信息披露义务人在安徽山河药用辅料股份有限公司 中拥有权益的股份变动情况；除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在安徽山河药用辅料股份有限公司中拥有权益的股 份。 四、本次权益变动是根据本报告所 ...